Skip to content

Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study

Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study (OCIN-AIS-EVT REGISTRY)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05864638
Enrollment
10000
Registered
2023-05-18
Start date
2023-05-10
Completion date
2028-08-31
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke, Large Vessel Occlusion, Thrombectomy, Thrombosis

Brief summary

A Multicenter Registry of Endovascular Treatment for Acute Ischemic Stroke.

Detailed description

The OCIN-AIS-EVT REGISTRY is a prospective, multicenter, blinded outcome evaluation, observational trial, and aims to determine the functional outcomes and safety of endovascular treatment for AIS, due to vessel occlusion in anterior and posterior circulation, in routine clinical practice. The primary endpoint is functional outcome, defined as a shift (improvement) in scores on the modified Rankin scale (mRS) at 90 days (±7 days).

Interventions

DEVICEEndovascular treatment

Endovascular treatment, such as mechanical thrombectomy with stent, aspiration catheter or stent assisted by intermediate aspiration catheter, as well as combination of mechanical thrombectomy with intra-arterial thrombolysis

Sponsors

Changhai Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Acute ischemic stroke caused by anterior or posterior circulation vessel occlusion confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA) or digital subtraction angiography (DSA) 2. Undergo intravascular therapy (i.e. access to a cath lab and an arterial puncture) 3. The patient or his/her legal representative agreed to participate in the study and has signed the informed consent.

Exclusion criteria

1\) No

Design outcomes

Primary

MeasureTime frameDescription
Functional outcome90daysShift (improvement) in scores on the modified Rankin scale (mRS) at 90 days (±7 days). The value range 0-6: higher scores mean a worse outcome.

Secondary

MeasureTime frameDescription
NIHSS at 24 hours24 hours post-procedureNational Institutes of Health Stroke Scale (NIHSS) score at 24 hours post- procedure. The value range 0-42: higher scores mean a worse outcome.
Dichotomized modified Rankin scale (mRS)90daysDichotomized modified Rankin scale (mRS) at 90 days after the procedure (0-1 versus 2-6, 0-2 versus 3-6, 0-3 versus 4-6). The value range 0-6: higher scores mean a worse outcome.
NIHSS at 7 days7 days post procedureNational Institutes of Health Stroke Scale (NIHSS) score at 7 days post procedure. The value range 0-42: higher scores mean a worse outcome.
Reperfusion outcomeImmediately post-procedureImmediate target vessel recanalization rate post-procedure: defined as proportion of subjects with extended thrombolysis in cerebral infarction (eTICI) score is 2b to 3 The value range 0-3: higher scores mean a better outcome.
Early successful revascularization rateDuring procedureEarly successful revascularization rate of target vessels by bridging therapy
Target vessel recanalization rateat 7 days post-procedureTarget vessel recanalization rate at 7 days post-procedure (assessed by CTA or MRA or DSA)

Other

MeasureTime frameDescription
Procedure related complicationwithin 30 days after procedureProcedure related complication
Device related complicationswithin 30 days after procedureDevice related complications
adverse events of special interestwithin 90 daysOther adverse events of special interest
Intracerebral hemorrhage(ICH)90 daysIntracranial hemorrhage, including symptomatic intracranial hemorrhage (sICH) and asymptomatic intracranial hemorrhage
Death7 days and 90 daysAll-cause death

Countries

China

Contacts

Primary ContactPengfei Yang, M.D.
15921196312@163.com86-21-31161784

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026